http://medrxiv.org This feed contains articles for medRxiv Subject Collection "Infectious Diseases" medrxiv https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png http://medrxiv.org https://www.medrxiv.org/content/10.64898/2026.07.01.26356762v1?rss=1 25 g/m3) on monthly TB notifications using Poisson regression with fixed effects for municipalities, state-by-year, and state-by-month, controlling for time-invariant differences, secular trends, and seasonality. Distributed lag effects were estimated over 1-24 months before notification. Models accounted for meteorological conditions, GeneXpert diagnostic coverage, and spatial correlation using Conley standard errors. We computed attributable fractions among exposed municipality-months (AFE). Sensitivity analyses evaluated alternative PM2.5 thresholds (15 and 35 g/m3), co-pollutants, and agricultural expansion. Findings From Jan 1, 2003 to Dec 1, 2023, 1,758,982 TB cases were reported. Of these, 353,319 (20.1%) had at least one high-exposure day (PM2.5 > 25 g/m3) 1-24 months before notification. An additional 14 high-exposure days over the 24-month lag period was associated with an average monthly increase of 2.9% [95% CI: 0.9-4.9%] in TB notification rates. Effects peaked at 13 months (IQR: 11-14) prior to notification. Results showed a dose-response relationship across PM2.5 thresholds and were robust to controlling for NO2, O3, and agricultural expansion. Overall, wildfire-related PM2.5 exposure accounted for 2.1% [0.7-3.5%] of TB notifications in exposed municipality-months, corresponding to 7,802 [2,612-12,544] attributable cases. The AFE reached 10.7% [7.1-14.0%] in Pantanal and 7.3% [6.1-8.5%] in Amazonia, areas most impacted by wildfires. Interpretation Wildfire-related PM2.5 exposure may represent an increasingly important and modifiable risk factor for TB. As wildfire activity increases across many regions of the world, these findings highlight the need for integrating air quality into climate adaptation and TB control strategies. ]]> 2026-07-04 doi:10.64898/2026.07.01.26356762 Cold Spring Harbor Laboratory 2026-07-04 https://www.medrxiv.org/content/10.64898/2026.07.01.26357075v1?rss=1 2026-07-04 doi:10.64898/2026.07.01.26357075 Cold Spring Harbor Laboratory 2026-07-04 https://www.medrxiv.org/content/10.64898/2026.06.30.26356813v1?rss=1 2026-07-01 doi:10.64898/2026.06.30.26356813 Cold Spring Harbor Laboratory 2026-07-01 https://www.medrxiv.org/content/10.64898/2026.06.27.26356737v1?rss=1 2026-07-01 doi:10.64898/2026.06.27.26356737 Cold Spring Harbor Laboratory 2026-07-01 https://www.medrxiv.org/content/10.64898/2026.06.24.26356242v1?rss=1 0.001). Cases were more likely to be born out of QECH than controls (42% vs. 24%, p = 0.043), and cases had lower birthweights (median 2200g vs. 2850g, p = 0.005). Multivariate logistic regression analysis revealed that increasing birthweight was protective against Kpn infection (OR: 0.858 [95% CI: 0.745-0.987] per 100g increase), while longer hospital stay was associated with increased odds of infection (OR: 1.148 [95% CI: 1.012-1.1.303] per additional day). Most infecting isolates (34/38 [89%]) were resistant to first- and second-line antimicrobial agents, but all were sensitive to meropenem and 33/36 [92%] to amikacin. ConclusionLow birthweight infants with prolonged hospital stay were at greatest risk of Kpn infections that were typically resistant to WHO first- and second-line antimicrobial therapy. These infants should be prioritised for antibiotics that have the potential to be life-saving. The overlapping and evolving nature of these risk factors makes it difficult to design a simple tool to support empiric initiation of meropenem. Neonates critically ill with Kpn sepsis cannot, however, afford to wait for blood culture-confirmation before receiving effective treatment. This highlights the need for empiric decision-making frameworks that allow rapid initiation of effective therapy in high-risk neonates. ]]> 2026-07-01 doi:10.64898/2026.06.24.26356242 Cold Spring Harbor Laboratory 2026-07-01 https://www.medrxiv.org/content/10.64898/2026.06.29.26356894v1?rss=1 View larger version (61K): org.highwire.dtl.DTLVardef@811a37org.highwire.dtl.DTLVardef@1e01b65org.highwire.dtl.DTLVardef@269856org.highwire.dtl.DTLVardef@1db6c8c_HPS_FORMAT_FIGEXP M_FIG C_FIG ]]> 2026-07-01 doi:10.64898/2026.06.29.26356894 Cold Spring Harbor Laboratory 2026-07-01 https://www.medrxiv.org/content/10.64898/2026.06.29.26356826v1?rss=1 48 hours meeting the entry criteria of the BM-AspICU algorithm were included. ETA galactomannan was measured and correlated with IPA classification. ResultsOf 120 patients, 37% (n=44) had probable IPA and 63% (n=76) were classified as colonisers or possible IPA. The optimal ETA galactomannan cut-off was 1.097, yielding sensitivity 72.73% (95% CI 57.2-85.0%), specificity 84.2% (95% CI 74.4-90.7%), PLR 4.86, NLR 0.35, and AUC 0.844 ConclusionETA galactomannan supports IPA diagnosis with favourable sensitivity and specificity. However, given the limitations of clinical scoring-based reference standards and the potential plateau in colonizer reduction at higher cut-offs, it should be integrated into a comprehensive diagnostic approach incorporating clinical, radiological, and microbiological criteria. ]]> 2026-07-01 doi:10.64898/2026.06.29.26356826 Cold Spring Harbor Laboratory 2026-07-01 https://www.medrxiv.org/content/10.64898/2026.06.29.26356773v1?rss=1 2026-07-01 doi:10.64898/2026.06.29.26356773 Cold Spring Harbor Laboratory 2026-07-01 https://www.medrxiv.org/content/10.64898/2026.06.24.26356490v1?rss=1 2026-06-29 doi:10.64898/2026.06.24.26356490 Cold Spring Harbor Laboratory 2026-06-29 https://www.medrxiv.org/content/10.64898/2026.06.25.26356514v1?rss=1 2026-06-29 doi:10.64898/2026.06.25.26356514 Cold Spring Harbor Laboratory 2026-06-29 https://www.medrxiv.org/content/10.64898/2026.06.24.26356481v1?rss=1 2026-06-29 doi:10.64898/2026.06.24.26356481 Cold Spring Harbor Laboratory 2026-06-29 https://www.medrxiv.org/content/10.64898/2026.06.16.26355774v1?rss=1 2026-06-26 doi:10.64898/2026.06.16.26355774 Cold Spring Harbor Laboratory 2026-06-26 https://www.medrxiv.org/content/10.64898/2026.06.15.26355542v1?rss=1 2026-06-26 doi:10.64898/2026.06.15.26355542 Cold Spring Harbor Laboratory 2026-06-26 https://www.medrxiv.org/content/10.64898/2026.06.24.26356444v1?rss=1 View larger version (54K): org.highwire.dtl.DTLVardef@1697a64org.highwire.dtl.DTLVardef@1e23cfcorg.highwire.dtl.DTLVardef@11c55borg.highwire.dtl.DTLVardef@b3eff7_HPS_FORMAT_FIGEXP M_FIG C_FIG Early innate immune signatures imprint host susceptibility and clinical outcomes to B. pertussis challenge. ]]> 2026-06-26 doi:10.64898/2026.06.24.26356444 Cold Spring Harbor Laboratory 2026-06-26 https://www.medrxiv.org/content/10.64898/2026.06.24.26356423v1?rss=1 2026-06-26 doi:10.64898/2026.06.24.26356423 Cold Spring Harbor Laboratory 2026-06-26 https://www.medrxiv.org/content/10.64898/2026.06.22.26356299v1?rss=1 96 % inclusivity; two sets exhibited reduced inclusivity (94.03 %, 90.14 %) and structural features potentially affecting binding against emerging variants. The assay enables direct identification of major VOCs (Alpha, Beta, Gamma, Delta, Omicron) and indirect detection of multiple VOIs (P.2, Epsilon, Kappa, Eta, Iota, Lambda). ConclusionThis standardized multiplex assay provides a rapid, sensitive, and low-cost alternative for SARS-CoV-2 variant surveillance in Cuba and similar settings. The integration of experimental and in silico validation offers a robust, adaptable framework to sustain diagnostic accuracy amid viral evolution, optimizing the allocation of scarce sequencing resources. Author SummaryGenomic surveillance is a cornerstone of the public health response to SARS-CoV-2, yet whole-genome sequencing capacity remains out of reach for many laboratories in low- and middle-income countries. To bridge this gap, we developed and validated a multiplex real-time RT-PCR assay that detects eight key mutations in the viral genome, enabling the identification of 11 priority lineages. The test costs approximately 5 USD per sample, produces results in a few hours, and uses standard thermocyclers -- making it suitable for decentralized deployment. Laboratory validation confirmed high diagnostic performance with no cross-reactivity against 32 other respiratory pathogens. Crucially, we combined this experimental work with a large-scale computational analysis of over 10 million publicly available viral genomes. This in silico step allowed us to verify that most of our primer and probe sets remain effective against global viral diversity, and to identify two sets that may require future optimization. Our work provides a practical, sustainable model for variant monitoring in settings with constrained sequencing capacity, as exemplified by Cuba. By integrating robust laboratory validation with ongoing bioinformatic surveillance, this framework optimizes the use of scarce genomic resources and strengthens pandemic preparedness in similar regions worldwide. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=111 SRC="FIGDIR/small/26356299v1_ufig1.gif" ALT="Figure 1"> View larger version (24K): org.highwire.dtl.DTLVardef@1b9ec6corg.highwire.dtl.DTLVardef@150bde8org.highwire.dtl.DTLVardef@1e3cf1forg.highwire.dtl.DTLVardef@133066c_HPS_FORMAT_FIGEXP M_FIG C_FIG ]]> 2026-06-25 doi:10.64898/2026.06.22.26356299 Cold Spring Harbor Laboratory 2026-06-25 https://www.medrxiv.org/content/10.64898/2026.06.23.26356359v1?rss=1 2026-06-25 doi:10.64898/2026.06.23.26356359 Cold Spring Harbor Laboratory 2026-06-25 https://www.medrxiv.org/content/10.64898/2026.06.22.26356273v1?rss=1 2026-06-25 doi:10.64898/2026.06.22.26356273 Cold Spring Harbor Laboratory 2026-06-25 https://www.medrxiv.org/content/10.64898/2026.06.22.26356210v1?rss=1 2026-06-25 doi:10.64898/2026.06.22.26356210 Cold Spring Harbor Laboratory 2026-06-25 https://www.medrxiv.org/content/10.64898/2026.06.18.26355521v1?rss=1 3,000 virus species) with Oxford Nanopore Flongle sequencing for easy and quick viral genome detection. The workflow includes random-primed cDNA synthesis, dsDNA conversion, TWIST probe enrichment, and Nanopore sequencing. Performance was evaluated using the QCMD 2024 Viral Metagenomics EQA panel and one clinical sample. ResultsAll expected targets of the QCMD 2024 Viral Metagenomics EQA panel were detected; eight of thirteen viruses achieved [≥]90% genome coverage. The negative control showed no targeted viral reads. Mixed infections of DNA and RNA viruses were resolved accurately. The workflow from nucleic acid extraction to obtaining sequence data was completed within 3 days. ConclusionsCombination of Flongle and hybrid-capture offers a rapid, sensitive sequencing method for detecting diverse viral genomes, suitable for outbreak response, urgent diagnostics, and surveillance of multiple divergent viruses at once. ]]> 2026-06-24 doi:10.64898/2026.06.18.26355521 Cold Spring Harbor Laboratory 2026-06-24 https://www.medrxiv.org/content/10.64898/2026.06.22.26356250v1?rss=1 2026-06-24 doi:10.64898/2026.06.22.26356250 Cold Spring Harbor Laboratory 2026-06-24 https://www.medrxiv.org/content/10.64898/2026.06.21.26356168v1?rss=1 2026-06-24 doi:10.64898/2026.06.21.26356168 Cold Spring Harbor Laboratory 2026-06-24 https://www.medrxiv.org/content/10.64898/2026.06.14.26355606v1?rss=1 2026-06-24 doi:10.64898/2026.06.14.26355606 Cold Spring Harbor Laboratory 2026-06-24 https://www.medrxiv.org/content/10.64898/2026.06.18.26355939v1?rss=1 2026-06-24 doi:10.64898/2026.06.18.26355939 Cold Spring Harbor Laboratory 2026-06-24 https://www.medrxiv.org/content/10.64898/2026.06.23.26355871v1?rss=1 2026-06-23 doi:10.64898/2026.06.23.26355871 Cold Spring Harbor Laboratory 2026-06-23 https://www.medrxiv.org/content/10.64898/2026.06.20.26356148v1?rss=1 2026-06-23 doi:10.64898/2026.06.20.26356148 Cold Spring Harbor Laboratory 2026-06-23 https://www.medrxiv.org/content/10.64898/2026.06.18.26355881v1?rss=1 2026-06-23 doi:10.64898/2026.06.18.26355881 Cold Spring Harbor Laboratory 2026-06-23 https://www.medrxiv.org/content/10.64898/2026.06.20.26356132v1?rss=1 2026-06-23 doi:10.64898/2026.06.20.26356132 Cold Spring Harbor Laboratory 2026-06-23 https://www.medrxiv.org/content/10.64898/2026.06.18.26355868v1?rss=1 500 genome copies/mL) were treated with artemether-lumefantrine (80mg/480mg at 8, 24, 36, 48 and 60 hours). From Day 28 following CHMI, participants attended a fortnightly clinic for clinical review and qPCR blood sampling, with additional assessments performed for any reported symptoms. P. vivax relapse infections (qPCR > 500 genome copies/mL) were treated with artemether-lumefantrine as per primary infection. Definitive anti-malarial treatment with atovaquone-proguanil (1000mg/400mg once daily for three days) and primaquine (0{middle dot}5 mg/kg/day for 14 days) was administered six months following CHMI, regardless of parasitaemia or symptoms. The primary objective was to assess the safety, feasibility and frequency of relapsing P. vivax after CHMI. Remote follow-up (5 years) is ongoing. The study is registered with ISRCTN registry (ISRCTN48625883). Findings20 participants were screened for eligibility from 21 January 2025. Five participants (median age 22 years) underwent CHMI (five infected mosquitoes per participant) on 15 April 2025. All participants developed primary P. vivax infection and experienced at least one relapse infection. Two participants experienced a second relapse. Overall incidence rate was 3{middle dot}6 relapse infections per person-year. Solicited adverse events were mild or moderate and there were no serious adverse events. Definitive anti-malarial treatment was administered to all participants. One participant experienced primaquine-induced methaemoglobinaemia, resolving with early discontinuation of treatment (total dose 5{middle dot}3 mg/kg). To date, more than six months after primaquine treatment, no further relapses have been recorded. InterpretationCHMI of relapsing P. vivax is safe and feasible, allowing exploration of the mechanisms underlying relapse infections and providing a platform for future anti-relapse efficacy studies. FundingEuropean Union Horizon Europe programme and UK Research and Innovation (UKRI) via OptiViVax consortium; UK National Institute for Health and Care Research Biomedical Research Centre: Oxford; and UK Medical Research Council. Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSRelapse infections account for the majority of cases of Plasmodium vivax malaria. There are no licensed vaccines for P. vivax and current anti-relapse hypnozoiticidal therapies (primaquine and tafenoquine) have restrictive contraindications, side effects and variable efficacy. A controlled human malaria infection (CHMI) model for relapsing P. vivax, using a well-characterised clonal isolate of P. vivax administered by mosquito bite, would present an opportunity to improve understanding of hypnozoite immuno-biology and provide a platform for efficacy studies of novel anti-relapse interventions. We searched PubMed on 23 April 2026 for research articles using the terms ("P. vivax" OR "Plasmodium vivax" OR "vivax") AND ("malaria challenge" OR "Controlled Human Malaria Infection" OR "CHMI" OR "sporozoite challenge"). No date or language filters were applied. The search identified seven published CHMI studies in which P. vivax was administered by mosquito bite. All these studies utilised mosquitoes infected from a source patient(s) with naturally-acquired infection, thereby limiting interstudy comparison and creating logistical challenges for reproducibility. Only one study reported relapse infections which occurred following primaquine treatment in two participants with poor and intermediate CYP2D6 metaboliser phenotype respectively. In addition to this PubMed search, historical records were identified which described the deliberate infection of humans with P. vivax i) in experiments conducted in the early 20th Century, and ii) as part of malariotherapy for the treatment of "general paralysis of the insane" (neurosyphilis). Although some of these records used well-characterised strains of P. vivax (e.g. Madagascar strain) and included relapse infections, these pre-dated modern molecular and serological laboratory techniques. Having previously generated a cryopreserved inoculum of P. vivax-infected red blood cells (PvW1) with high-quality genome assembly, we set out to administer this clonal isolate in a CHMI study by mosquito bite, and characterise P. vivax relapse infections over a six-month period prior to the administration of primaquine treatment. Added value of this studyThis study reports the administration of PvW1 by mosquito bite to five healthy adult participants in the UK. All participants developed primary P. vivax infection and experienced at least one relapse infection in a six-month follow-up period. Two participants experienced a second relapse infection prior to the administration of definitive anti-malarial treatment with atovaquone-proguanil and primaquine. Solicited adverse events (foreseeable symptoms of malaria) were mild or moderate. Long-term remote follow-up is ongoing. However, to date, more than six months after primaquine treatment, no further relapse infections have been recorded. To our knowledge, this is the first CHMI study in the modern era to administer a well-characterised clonal isolate of P. vivax by mosquito bite. We demonstrate that a CHMI model for relapsing P. vivax is safe and feasible. Implications of all the available evidenceThe World Health Organisation (WHO) Technical Brief on the Control and Elimination of Plasmodium vivax Malaria calls for better understanding of the biology and epidemiology of P. vivax, and the development of new interventions and strategies. Specifically, it highlights a need for improved knowledge of the underlying mechanisms of P. vivax relapse infections; a single-dose hypnozoiticidal treatment that can be used for all population groups without significant side effects; and development of P. vivax vaccines. CHMI studies allow the study of host-pathogen interactions in detail and accelerate the development of vaccines and therapeutic drugs by providing evidence of efficacy early in clinical development. This proof-of-concept study presents an opportunity to explore the mechanisms behind hypnozoite formation and activation in humans, and provides a novel clinical platform for future drug and vaccine efficacy studies. ]]> 2026-06-22 doi:10.64898/2026.06.18.26355868 Cold Spring Harbor Laboratory 2026-06-22 https://www.medrxiv.org/content/10.64898/2026.06.16.26355753v1?rss=1 10 parasites/{micro}L or symptom onset, participants received oral gametocyte-sparing treatment (GST): mepacrine (Cohort 1 and 3; 100 mg at 0, 8 16 hours, then once daily for 3 days) or piperaquine (Cohort 3; 480 mg single-dose). Transmission was assessed by direct skin feeding (DSF) and membrane feeding assay (DMFA) with and without enrichment of gametocytes. End-of-study treatment was atovaquone-proguanil (1000/400 mg once daily for 3 days). The trial was registered: NL-OMON57011. FindingsParticipants were enrolled between September 17, 2024 and March 25, 2025, all (12/12) developed parasitemia and transmitted PvW1 to mosquitoes. No serious adverse events occurred. Most adverse reactions were related to malaria. Mepacrine and piperaquine reduced asexual parasitemia while preserving gametocytemia and transmission. Peak transmission occurred within 3 days after GST and depended on the parasite developmental cycle, with highest gametocyte-infectivity [~]48 h post ring-stage. In Cohort 3, mosquito infection reached 100% in all transmission assays. Median peak oocyst counts were 24 (IOR: 14-31) for DSF, 17 (12-19) for DMFA, and 150 (116-199) for enriched DMFA. A two-fold increase in pre-GST maximal parasitemia was associated with 20 additional oocysts (95% CI 8{middle dot}6-32) in enriched DMFA. Sporozoites were viable in primary human hepatocytes. InterpretationA PvW1 transmission-CHMI is reproducible and safe, enabling P. vivax sporozoite production, relapse models and evaluation of transmission-blocking interventions. FundingThe OptiViVax project is supported by European Union Horizon Europe programme and UK Research and Innovation (UKRI); Swiss Governments State Secretariat for Education, Research, and Innovation (SERI); National Institute for Health and Care Research Oxford Biomedical Research Centre (NIHR-BRC). Research in contextO_ST_ABSEvidence before this studyC_ST_ABSIn its Malaria Vaccine Technology Roadmap, the World Health Organization prioritizes Plasmodium vivax research and vaccine development alongside Plasmodium falciparum. Controlled human malaria infections (CHMI) play an important role in the development of new interventions as they enable early evaluation of new drugs and vaccines in small groups of participants. Added value of this studyTo our knowledge this is the first study to achieve consistent transmission of a P. vivax clone to mosquitoes following blood-stage P. vivax CHMI. Reproducible high-level transmission was observed both in direct feeding assays and after gametocyte enrichment and parameters were identified that improve transmission success. It is also the first P. vivax CHMI trial that systematically assessed the use of piperaquine and mepacrine to attenuate asexual replication while preserving transmission-competent gametocytes. Implications of all the available evidenceThis study expands the repertoire of P. vivax CHMI models and builds on the success and knowledge of prior P. vivax and P. falciparum CHMIs. This optimised transmission model enables production of highly infected mosquitoes and sporozoites for downstream use with a genetically-defined clone, which is particularly important for P. vivax because it cannot be maintained in continuous culture. It also facilitates evaluation of transmission-blocking interventions. ]]> 2026-06-22 doi:10.64898/2026.06.16.26355753 Cold Spring Harbor Laboratory 2026-06-22